ArticleBritish journal of cancer2018

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.

Keith Dredge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.